

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 October 2018 (04.10.2018)



(10) International Publication Number
WO 2018/183385 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 14/725 (2006.01)
A61K 38/00 (2006.01) C07K 14/705 (2006.01)
A01N 63/00 (2006.01) C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/US2018/024650

(22) International Filing Date:

27 March 2018 (27.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/477,335 27 March 2017 (27.03.2017) US
62/628,774 09 February 2018 (09.02.2018) US

(71) Applicants: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). NKARTA, INC. [US/US]; 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: LEONG, Jun, Hao; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SHIMASAKI, Noriko; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SEOW, See, Voon; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). CAMPANA, Dario; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). TRAGER, James, Barnaby; c/o Nkarta, Inc., 329

Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). LAZETIC, Alexandra, Leida Liana; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). GUO, Chao; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). BUREN, Luxuan, Guo; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). MASRANI, Shyam, Sashikant; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US).

(74) Agent: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Rd., P.O. Box 9133, Concord, MA 01742-9133 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN NATURAL KILLER CELL IMMUNOTHERAPY




FIG. 1B

(57) Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*